Benefits of MR-proADM

Optimize risk assessment, decision making and treatment processes


MR-proADM is a blood biomarker that provides accurate short-, mid- and long-term prognostic information and aids in the triage and multi-dimensional risk assessment of patients in the Emergency Department (ED) and Intensive Care (ICU) settings.

Plasma concentrations are increased in proportion to disease severity due to an increase in blood vessel vasodilation and endothelial damage. In developing disease conditions, increasing MR-proADM concentrations during hospitalization can warn the treating physician of the development of potential complications or overall treatment failure before the patient shows any clinical signs of deterioration, thus allowing the timely transfer to a more acute hospital setting. Conversely, low MR-proADM concentrations can provide the treating physician with confidence that their patient is not at risk, nor is likely to develop any significant clinical conditions.


Key features and benefits


Increased patient safety
Increased patient safety through a more accurate clinical risk assessment


early warning of developing complications
An early warning of developing complications


Decrease in-patient numbers
Decrease in-patient numbers and increase out-patient treatment


decrease a patient’s length of stay
Significantly decrease a patient’s length of stay by transferring or discharging when there is no significant clinical risk


Reduced healthcare resource consumption
Reduced healthcare resource consumption


earliest warning of treatment failure
The earliest warning of treatment failure, and optimize treatment strategies


thermo scientific applied biosystems invitrogen fisher scientific unity lab service